Program
sofetabart mipitecan
Also written as “Sofe-M” and “Sofetabart Mipitecan”.
Its studies are mostly in Ovarian Neoplasms, led by Eli Lilly.
Furthest: phase 3, since Oct 7, 20252 company-led studies, 2 open or runningNext primary completion: Nov 2028 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lilly | 22 open or running | phase 3since Oct 7, 2025 | Apr 30, 2024 | Nov 2028phase 3 · NCT07213804 |
- Named in Eli Lilly’s own pipeline as
Sofetabart Mipitecan
, phase 3, as of Oct 29, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 30, 2024First study: phase 1 study in Ovarian NeoplasmsFirst studyNCT06400472 · 575 planned · United States, Australia, France and more
- Oct 7, 2025Phase 3 study in Ovarian NeoplasmsNCT07213804 · 1,630 planned · United States, Australia, Austria and more
Ahead
- Nov 2028Primary completion: phase 3 study in Ovarian NeoplasmsNCT07213804
- Jun 2029Primary completion: phase 1 study in Ovarian NeoplasmsNCT06400472
TargetBeta
“An antibody-drug conjugate (ADC) composed of a Fc-silenced, humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting folate receptor alpha (FRa; FolRa; FOLR1) linked, via a dipeptide cleavable linker and a polysarcosine hydrophobicity masking agent, to the camptothecin analog and topoisom…”NCIt, read by Claude
“An antibody-drug conjugate (ADC) composed of a Fc-silenced, humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting folate receptor alpha (FRa; FolRa; FOLR1) ”NCIt, by rule
Other programs on FOLR1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| mirvetuximab soravtansinerule | AbbVie | phase 3 | 15 |
| rinatabart sesutecanrule | Genmab | phase 3 | 9 |
| torvutatug samrotecan | AstraZeneca | phase 3 | 5 |
| opugotamig olatansine | AbbVie | phase 2 | 2 |
| Anti-Folate Receptor Alpha Antibody-drug Conjugate ABBV-901 | AbbVie | phase 1 | 1 |
| Anti-FRa/Anti-CD3 Bispecific TCE NTB-928rule | teneoseven-inc | phase 1 | 1 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07213804Ovarian Neoplasms · United States, Australia, Austria and more | 3 | Recruiting | Nov 2028 | 1,630 |
| NCT06400472Ovarian Neoplasms · United States, Australia, France and more | 1 | Recruiting | Jun 2029 | 575 |
How it is read
Names in the registry
- “Sofe-M”, 1 entry
- “Sofetabart Mipitecan”, 1 entry
Conditions, from the studies’ own filings
- Ovarian Neoplasms, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.